AltPep Corporation
100 NE Northlake Way
STE 300
Seattle
WA
98105
United States
Tel: +1 (425) 658-0277
Website: http://www.altpep.com/
Email: info@altpep.com
About AltPep Corporation
AltPep, a startup located in Seattle Washington, is developing early disease-modifying treatments and detection tools for amyloid diseases by targeting one of the earliest molecular triggers – toxic soluble oligomers. These oligomers are associated with many diseases, including neurodegenerative diseases and type 2 diabetes. Decades of scientific research by the Daggett Research Group culminated in the discovery of a novel protein structure, alpha-sheet, the foundation of our innovative approach.
Our lead program aims to identify Alzheimer’s Disease long before symptoms occur and then neutralize the toxic soluble oligomers associated with the disease.
2 articles with AltPep Corporation
-
AltPep Receives FDA Breakthrough Device Designation for SOBA-AD, A Simple Blood Test for the Detection of Alzheimer’s Disease
3/1/2022
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the U.S. Food and Drug Administration (FDA) granted the company Breakthrough Device designation for its SOBA-AD diagnostic in development for Alzheimer’s disease (AD).
-
AltPep Appoints Nancy Hill to Newly Created Position of Chief Product Officer
2/24/2022
AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer.